ECM
ADPT icon

Evergreen Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Evergreen Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-38,086
Closed -$1.06M – 398
2020
Q1 		$1.06M Buy
+38,086
New +$1.06M 0.1% 163

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Evergreen Capital Management's ADPT Position: Q2 2020 in Review

Evergreen Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2020, closing a stake of 38,086 shares — an estimated $1.06M sold.

Evergreen Capital Management first reported a position in ADPT in Q1 2020 and held it in 1 quarter. The position peaked at $1.06M in Q1 2020. 196 funds tracked by Wall St. Rank hold ADPT as of Q2 2020.

  • Evergreen Capital Management reported no remaining Adaptive Biotechnologies position as of Q2 2020 after selling out during the quarter.
  • Evergreen Capital Management sold 38,086 Adaptive Biotechnologies shares in Q2 2020, an estimated $1.06M.
  • Evergreen Capital Management first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 1 quarter.
  • Evergreen Capital Management's Adaptive Biotechnologies position peaked at $1.06M in Q1 2020.
  • 196 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2020.

Based on Evergreen Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.